FDA Converts Pembrolizumab Approval for High Mutation Burden Tumors

The FDA has granted traditional approval to pembrolizumab, marketed as Keytruda, and a combination formulation with berahyaluronidase alfa pmph, for adult and pediatric patients with unresectable or metastatic tumor mutational burden high solid tumors, according to an FDA announcement. This is an approved oncology therapy, not an investigational compound, and the update changes how the indication is defined.

Pembrolizumab first received accelerated approval for tumors with a mutational burden of at least 10 mutations per megabase. The new action converts that into full approval but narrows the qualifying threshold to at least 13 mutations per megabase, since the agency says efficacy for the 10 to under 13 range was not confirmed in follow up data.

Supporting evidence came from the KEYNOTE 158 trial, where patients with tumors at or above the revised threshold who had already progressed on prior treatment and had no satisfactory alternatives received pembrolizumab. Across 220 evaluable patients, the objective response rate was 36 percent, and more than half of responders maintained that response for a year or longer. The safety profile matched what is already known for pembrolizumab, including immune mediated reactions and infusion related events.

This case is a reminder that accelerated approvals are provisional and can be revised as more data accumulates.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.